bluebird bio’s Post

It's almost time for the OutcomeRX team (Joe Morse, Kirby Eng, Brooks Wildasin, and Greg Arms ) to head to Phoenix for the 2023 SIIA National Convention! Throughout the past year, one of the most relevant topics in the space has been cell and gene therapies (CGTs) and their impact on claim costs. OutcomeRx has been working diligently on Patient Access to Costly and Curative Therapies (PACCT), offering the protection needed for financial stability while providing life-altering therapies to plan members. Before deciding to exclude CGTs, discover how we're simplifying access and addressing the cost challenge. Let's connect at the convention and explore the future of self-insurance together! #SIIA2023 #SelfInsurance #CGTTherapies #Innovation

In this new report from UCL Business Ltd you can read about how gene therapy company MeiraGTx is developing potentially curative therapies for inherited eye disease based on research at UCL Institute of Ophthalmology. uclb.com/impact (p.9) #UCLBimpact

Meet with us at the 3rd Innovative Therapies Days conference today and tomorrow 💬 💊!   Dr. Dilyana DIMITROVA, PhD, will be present and more than happy to discuss the new data single-cell could uncover for cell and gene therapies or CAR-T cells. This will also be the opportunity to discover the simplest way to implement a single-cell workflow for your groundbreaking project. Do not hesitate to schedule a meeting with her via the conference platform, and let’s work together to accelerate the path toward new therapies! You can also contact us at info@scipio.bio for more information. #singlecell #ITD #celltherapy"

📣 Keara Sutherland, will present at Boston's Lab of the Future Congress! Join her and learn how Virica Biotech combines its high-throughput virology platform with the power of Synthace and DoE (design of experiments) for rapid and simultaneous vector production optimization. Biomanufacturing cell and gene therapies is complex and intricate, with a lot of variability. 💡 Combining the statistical power of DoE with high-throughput virology is a game changer. 🤝 If you are attending, Keara would love to connect and talk about automation, DoE and more! #LabOfTheFuture #ViralVectorOptimization #DoE 

🚀 Gearing up for the "Meeting on The Mesa" in Carlsbad, California from October 10th-12th! This event gathers the cell and gene therapy community to explore advancements in the field, cultivate business relationships, and brainstorm ways to enhance the lives of patients globally. Ori Biotech's very own Jason C. Foster will be taking the stage at 12 PM PST on the 10th in the Rentschler ATMP Ballroom. He'll share insights on our ongoing mission to ensure widespread patient access to life-saving cell and gene therapies. Additionally, we're hosting a cross-industry workshop to delve into the potential of digital and data in our sector. While there's consensus on the benefits of digitalization—like cost reduction, time-saving, and quality enhancement—the industry still grapples with leveraging these advantages fully. What do you think the main challenges are? This engaging session is slated for post-lunch on Thursday, October 12th. Hurry, as we only have three spots left! If you're keen to participate, drop me a message. The Ori Biotech team will be present throughout the event. If you'd like to discuss any of the sessions or are curious about our mission, don't hesitate to reach out! #celltherapy #genetherapy #digital #innovation #data #biotechnology

Have you had a chance to explore our recent whitepapers? Would you like to revisit the ones that caught your attention? Over the last four weeks, we published four whitepapers looking at a different aspect of how #DecentralizedManufacturing of cell and gene therapies can be achieved and used to increase accessibility for rural and global communities. You can read the entire series here: www.realm.bio/insights A BIG thank you to everyone who collaborated with us and helped to create this series! Domhnall Mc Gowan, Erika Francoeur, Craig Hasilo, Jenny Ligon, Stephen Stewart, and Enayat Mohammad, PMP

I had the pleasure of joining Stuart Lowe in the latest episode (Episode 8) of TTP plc’s Invent Life Sciences podcast 🎙️, and we dove deep into the world of Process Analytics. 🔬 In this episode, we explored how analytics are revolutionising the development and manufacture of cell and gene therapies. We delved into the critical role that analytics play in characterising processes and products, ensuring the utmost precision and quality in the field of life sciences. 🧬 We touched on the technical and even somewhat philosophical thinking around the future of #processanalytics in #cellandgenetherapy With the constant innovation in life sciences, it’s fascinating to see how new technologies are being implemented to keep up with the fast pace of developments. Do the current process analytical tools provide the insights therapy developers need? How can we harness new technologies to drive progress? 🚀 Tune in now to discover the answers to these questions and gain insights into the future of life sciences! 🌟 #LifeSciences #Innovation #ProcessAnalytics #PodcastEpisode

The final episode of the series is here!

⌛ “It’s time to elevate the third pillar of CGT: viability” - Carl Schoellhammer In our newest Ori Spotlight podcast episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs). Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles. 🎧 Listen on Spotify: https://lnkd.in/gmWCkpgG #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

This #worldthalassaemiaday24, we remember an estimated 100 million people worldwide carrying the genes responsible for thalassaemia and more than 300,000 babies born annually with severe forms of the disease. With exciting breakthroughs in cell and gene therapies offering new hope for those living with thalassaemia, it is time to unite efforts towards supporting unrestricted and equitable patients’ access to all approved, effective and safe treatment options regardless of cost and help them live their lives to the fullest. This World Thalassaemia Day, ARISE joins the fight for unrestricted and equitable access to these potentially life-changing treatments. Everyone deserves the chance to live a full and healthy life, regardless of cost. We also recognise the shared responsibility to empower individuals with thalassaemia through awareness and advocacy. Together, we can empower patients and embrace progress. #treatmentforall #ITD2024 #worldthalassaemiaday2024